ImmunityBio (IBRX) Global Expansion Bolsters 266% Jump This Year

ImmunityBio Inc. (NASDAQ:IBRX) is one of the 11 Stocks With 3x-5x Returns This Year.

ImmunityBio has seen its price surge by 266 percent year-to-date—with shares already at $7.25 versus only $1.98 on December 31—with investor appetite primarily fueled by growth prospects from its future global expansion to 34 new markets.

This followed developments from its bladder cancer treatment, Anktiva, which propelled the company’s full-year 2025 revenues by 671 percent to $113 million from only $14.7 million in 2024, reflecting strong adoption for the treatment, with sales volume expanding by 750 percent.

ImmunityBio (IBRX) Climbs 7.3% as Firm Nears Development of 'World Bank of NK Cells'

Photo by Anthony Shkraba on Pexels

ImmunityBio Inc. (NASDAQ:IBRX) is set to expand its sales operations for Anktiva into the US, the UK, Saudi Arabia, Macau, and Europe after receiving the go-signal from their regulators. Its entry into the said jurisdictions opens the doors for further revenue expansion.

To support the initiative, ImmunityBio Inc. (NASDAQ:IBRX) successfully raised $100 million in fresh funds, of which $75 million was drawn from a non-dilutive financing from Oberland Capital, while another $25 million was raised from a debt-to-share conversion by Nant Capital LLC, a company affiliated with ImmunityBio Inc. (NASDAQ:IBRX) Chairman Patrick Soon-Shiong.

“We are engaging with additional health authorities across the Asia-Pacific region and, in parallel, beginning to prepare for potential commercial distribution, recognizing there is still meaningful work ahead as we pursue further regulatory authorizations. Our focus is on executing this expansion in a disciplined manner, building on our existing approvals to support long-term global access for patients,” said ImmunityBio Inc. (NASDAQ:IBRX) President and CEO Richard Adcock.

While we acknowledge the risk and potential of IBRX as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than IBRX and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.